CyMed

CytoMed Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel cell-based immunotherapies for the treatment of various cancers. Headquartered in Singapore, the company leverages its proprietary platform to create "off-the-shelf" allogeneic cell therapies using natural killer (NK) cells and gamma delta T cells. Their lead candidate, CTM-N2D, is a chimeric antigen receptor (CAR)-modified gamma delta T cell therapy currently in Phase 1 clinical trials for solid tumors. CytoMed aims to address the limitations of current autologous CAR-T therapies by providing more accessible and cost-effective treatment options through induced pluripotent stem cell (iPSC) technology.